CJC-1295 (No DAC),Synthetic growth hormone-releasing hormone (GHRH) analogue widely utilised in peptide and endocrine pathway research
When defending its position, Caremark cited cost concerns and the availability of preferred, therapeutically interchangeable medications (like those made by Zepbounds competitor, Novo Nordisk)
Zhang XL, Feng YL Zhou BA & Wei GY
She added that there is "also concern for loss of bone density and muscle mass if protein intake and resistance activity are inadequate." "These medications do not distinguish between fat and lean mass, so without proper nutrition, patients can lose both," she said
Understanding this rebound effect helps explain why GLP-1 therapy is designed as a long-term treatment rather than a short-term fix
While both peptides aim to boost HGH levels, they operate through distinct mechanisms, offering unique advantages depending on individual health goals